170045 20260316092630.0 doi 10.1016/j.addr.2026.115836 sideral 148624 ART-2026-148624 eng Guerrero-López, Paula Universidad de Zaragoza (orcid)0000-0003-3661-7718 Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing 2026 Drug delivery research strongly depends on experimental models that faithfully mimic the tumor microenvironment (TME) and its barriers to evaluate therapeutic efficacy. Conventional systems provide valuable insights but suffer from some limitations in physiological relevance, reproducibility, scalability or translational predictability. In this context, microfluidic ‘tumor-on-chip’ platforms have emerged as innovative tools that integrate engineering technology to model biological complexity, offering controlled microenvironments to investigate drug penetration, transport dynamics, and therapeutic response. A distinctive aspect of these microsystems is the possibility of incorporating matrices that mimic the extracellular matrix (ECM) of different tissues. These matrices enhance the ability of the in vitro models to replicate the structural, biochemical, and mechanical features of solid tumors. In this review, we focus on the application of microfluidic matrix-integrated tumor-on-chip platforms for drug delivery evaluation. We first outline key microenvironmental features that regulate therapeutic efficacy and discuss how they can be engineered within microfluidic models. We then examine how transport dynamics and delivery mechanisms are modeled under physiologically relevant conditions and review the use of these platforms to assess a broad range of therapeutic strategies, including nanocarriers, biologics, and gene- and cell-based therapies. Finally, we highlight emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools. These models aim to bridge the gap between simplified in vitro assays and more complex in vivo studies, ultimately accelerating the translation of drug delivery systems into clinical practice and paving the way for more personalized therapeutic strategies. Access copy available to the general public Unrestricted info:eu-repo/grantAgreement/EC/H2020/101018587/EU/Individual and Collective Migration of the Immune Cellular System/ICoMICS This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 101018587-ICoMICS info:eu-repo/grantAgreement/ES/MCIU/PID2024-155384OB-C21 info:eu-repo/semantics/openAccess by-nc https://creativecommons.org/licenses/by-nc/4.0/deed.es info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Alamán-Díez, Pilar Universidad de Zaragoza (orcid)0000-0003-1958-4432 Hernández-Hatibi, Soraya Universidad de Zaragoza Balsas, Patricia Universidad de Zaragoza (orcid)0000-0002-9485-9179 García-Aznar, José Manuel Universidad de Zaragoza (orcid)0000-0002-9864-7683 5004 605 Universidad de Zaragoza Dpto. Ingeniería Mecánica Área Mec.Med.Cont. y Teor.Est. 5001 065 Universidad de Zaragoza Dpto. Ciencia Tecnol.Mater.Fl. Área Cienc.Mater. Ingen.Metal. 232 (2026), 115836 [24 pp.] Adv. drug deliv. rev. ADVANCED DRUG DELIVERY REVIEWS 0169-409X 4675209 http://zaguan.unizar.es/record/170045/files/texto_completo.pdf Versión publicada 1962102 http://zaguan.unizar.es/record/170045/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:170045 articulos driver 2026-03-16-08:17:32 ARTICLE